Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy

Crizotinib is a multi-targeted tyrosine kinase inhibitor (TKI) with activity against mesenchymal-epithelial transition factor (MET) and anaplastic lymphoma kinase (ALK) [1]. Driver oncogenes are conventionally considered mutually exclusive [2]. Here, we describe a rare case of lung adenocarcinoma harboring concomitant spectrin beta non-erythrocytic 1 (SPTBN1)-ALK fusion, c-Met overexpression, and human epidermal growth factor receptor-2 (HER-2) amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy.

In July 2015, a 69-year-old never-smoker man, whose brother died of lung cancer, experiencing pain in his low back and left lower extremity, underwent a total-body positron emission tomography-computed tomography (PET/CT) scan which showed a lung tumor and bone metastases (Fig. 1d–f). Then, a CT-guided percutaneous lung biopsy was performed (Fig. 1a), and a diagnosis of advanced lung adenocarcinoma was made. Based on the immunohistochemistry analysis, the tumor cells were negative for ALK (Fig. 1c) but extremely positive for c-Met (Fig. 1b). In addition, epidermal growth factor receptor (EGFR) mutation and repressor of silencing 1 (ROS-1) fusion detections revealed negative results.

The patient initially received gemcitabine plus nedaplatin for one cycle in July 2015. Subsequent treatment included palliative radiation therapy to the left ilium. Additionally, the patient was treated with crizotinib based on c-Met overexpression. However, grade 3 thrombocytopenia occurred after chemotherapy, and he recovered with recombinant human thrombopoietin. Although the symptoms decreased, first restaging CT scans (September 2, 2015) showed marked worsening disease (Additional file 1: Figure S1a).

Then, the patient received two cycles of bevacizumab-based chemotherapy with pemetrexed, cisplatin, and bevacizumab from September to October in 2015. Additionally, he received local radiotherapy at the lumbar metastases. However, lumbar MRI and CT scan of the chest and abdomen (October 2015) showed progressive disease (Additional file 1: Figure S1b).

Given the patient’s reduced performance status, reduced paclitaxel liposome plus nedaplatin was administered (October 27, 2015). Subsequent treatments included iAPA DC-CIK and chest radiotherapy. However, the patient demonstrated evidence of progressive disease again in December 2015 (Additional file 1: Figure S1c). To re-evaluate the molecular characteristics, DNA extracted from the original biopsy was used for DNA sequencing with next-generation sequencing on December 2015. Interestingly, the patient had HER-2 amplification and a novel ALK rearrangement, namely SPTBN1-ALK fusion, which was created by an insertion between two breakpoints in exons 1 to 6 of the SPTBN1 gene and exons 20 to 29 of the ALK gene (Fig. 2). Given the patient’s performance interfered with starting chemotherapy, he was treated with whole-brain irradiation therapy. However, the patient’s performance status continuously deteriorated. On January 4, 2016, the patient died of brain and lung metastases. The patient’s overall survival was only 8 months.

The SPTBN1-ALK fusion gene was first identified in colorectal cancer, which was formed by the fusion of exon 7 of the SPTBN1 gene with exon 20 of the ALK gene [3]. In this case, we first identified a novel SPTBN1-ALK fusion in lung cancer. The frequency of c-Met overexpression is 31.9 % in NSCLC, and it potentially causes intrinsic resistance to EGFR-TKIs without causing resistance to crizotinib [4]. Nonetheless, the present patient gained inherent crizotinib resistance despite harboring both c-Met overexpression and the SPTBN1-ALK fusion gene. HER-2 is noted in 10 to 20 % of NSCLC patients [5] and confers relative resistance to conventional chemotherapy [6]. The novel ALK rearrangement and interactive crosstalk between Met and HER2 may have been responsible for the failed response to crizotinib treatment. In this context, inhibition of ALK, Met, and Her-2 was required for efficient inhibition of tumor growth.

To the best of our knowledge, this is the first case of lung cancer with a novel SPTBN1-ALK fusion gene, which may become a potential target for anti-tumor therapy. This interesting case demonstrates that c-Met overexpression, HER-2 gene amplification, and SPTBN1-ALK gene fusion can coexist in lung adenocarcinoma, and their combination might be a biomarker for resistance to crizotinib, traditional chemotherapy, and radiotherapy as well as for a relatively poor prognosis. Further evidence is required to validate these preliminary data.

ALK, anaplastic lymphoma kinase; CIK, cytokine-induced killers; DC, dendritic cell; EGFR, epidermal growth factor receptor; HER-2, human epidermal growth factor receptor-2; iAPA, inhibition of antigen presentation attenuators; MET, mesenchymal-epithelial transition factor; MRI, magnetic resonance imaging; NSCLC, non-small-cell lung cancer; PET/CT, positron emission tomography-computed tomography; ROS1, repressor of silencing 1; SPTBN1, spectrin beta non-erythrocytic 1; TKI, tyrosine kinase inhibitor